Nivolumab + Tegafur-gimeracil-oteracil potassium + Oxaliplatin + Capecitabine + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Jan 31, 2017 → Mar 31, 2023
NCT ID
NCT03006705About Nivolumab + Tegafur-gimeracil-oteracil potassium + Oxaliplatin + Capecitabine + Placebo
Nivolumab + Tegafur-gimeracil-oteracil potassium + Oxaliplatin + Capecitabine + Placebo is a phase 3 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03006705. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03006705 | Phase 3 | Completed |
Competing Products
20 competing products in Gastric Cancer